A Bayesian Approach to the Design of Phase II Clinical Trials
DOI10.2307/2531594zbMATH Open0715.62243OpenAlexW2329151889WikidataQ52553011 ScholiaQ52553011MaRDI QIDQ3201545FDOQ3201545
Publication date: 1988
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2531594
Recommendations
- Approximately optimal designs for phase II clinical studies
- Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
- A Bayesian decision approach for sample size determination in phase II trials
- Bayesian Optimal Design for Phase II Screening Trials
- Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies
hypothesis testdecision theoryrisk functionsample sizesmedicinedrug screeningdesign of Phase II clinical trials
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)
Cited In (30)
- Bayesian design for clinical trials with a constraint on the total available dose
- Adaptive data collection for intraindividual studies affected by adherence
- Title not available (Why is that?)
- MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
- Bayesian Approaches to Randomized Trials
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers
- Bayesian design of biosimilars clinical programs involving multiple therapeutic indications
- Bayesian statistics and the efficiency and ethics of clinical trials
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
- Approximately optimal designs for phase II clinical studies
- Design and Analysis of Phase II Cancer Trials: A Review of Statistical Methods and Guidelines for Medical Researchers
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome
- Determination of the optimal sample size for a clinical trial accounting for the population size
- Approaches for Optimal Sequential Decision Analysis in Clinical Trials
- Bayesian design of clinical trials using joint cure rate models for longitudinal and time-to-event data
- Bayesian Design and Analysis of Active Control Clinical Trials
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
- Optimal Bayesian two-phase designs
- Title not available (Why is that?)
- Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
- Bayesian randomized clinical trials: A decision-theoretic sequential design
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Bayesian Optimal Design for Phase II Screening Trials
- Use of bayesian analysis to design of clinical trials with one treatment
- Title not available (Why is that?)
- Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach
- Bayes rules for a clinical-trials model with dichotomous responses
- Bayesian doubly adaptive randomization in clinical trials
This page was built for publication: A Bayesian Approach to the Design of Phase II Clinical Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3201545)
